Immunotherapy is reshaping treatment for pemphigus and bullous pemphigoid with promising results from biologics like rituximab and dupilumab. Learn how precision immunology is advancing care.

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...

The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...

The FDA approved Dupixent for the treatment of adults with bullous pemphigoid, a rare skin disease often uncontrolled with ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Further expanding the indications for French pharma major Sanofi’s (Euronext: SAN) mega-blockbuster Dupixent (dupilumab), the ...

IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...